February 2026 Research Update

What became clearer this month

This month added clearer framing for how LAM can be recognized among the many causes of lung cysts: imaging patterns help sort the possibilities, and a blood marker (VEGF-D) can support the diagnosis but does not cleanly separate everyone. A step-by-step CT-based approach emphasizes first confirming a true lung cyst and then narrowing down which diffuse cystic lung disease fits best, including LAM. In a real-world group of women with multiple lung cysts, VEGF-D was usually higher in LAM than in other look-alike conditions, but some people with LAM-like imaging still had VEGF-D below a commonly used cutoff. [1] [2]

One study focusing on VEGF-D found it separated definite LAM from non-LAM reasonably well, with an overall diagnostic performance (AUC) of 0.866. Using a cohort-derived cutoff of 738 pg/mL gave 81% sensitivity and 79% specificity, while the guideline cutoff of 800 pg/mL identified 75% of LAM cases in that cohort. A key practical point from the report is that a minority of people who otherwise looked like LAM on HRCT and/or had typical features outside the lungs had VEGF-D below 800 pg/mL. [2]

A separate paper laid out a structured CT-based diagnostic pathway for cystic lung findings, aiming to reduce confusion between true cysts and conditions that mimic cysts. After confirming true cysts, the algorithm highlights CT patterns and related body findings that can point toward LAM versus other diffuse cystic lung diseases such as Birt-Hogg-Dube syndrome or pulmonary Langerhans cell histiocytosis. This kind of framework matters because many different diseases can look similar at first glance on chest imaging. [1]

What this may mean for patients and caregivers

For patients, the main update is a clearer picture of why LAM diagnosis often uses more than one piece of evidence: chest imaging patterns, signs elsewhere in the body, and sometimes a blood test like VEGF-D. The VEGF-D study supports that higher VEGF-D levels are common in LAM, but it also shows why a single cutoff cannot perfectly include everyone who has LAM-like imaging. This is human clinical research, but it comes from a single center and needs validation in broader groups, so it mainly adds understanding about how diagnosis can be supported rather than providing a final answer for every individual. [2] [1]

What these individual cases add

This month included two case reports that broaden the picture of how LAM and related cell types can appear across organs, especially in connection with tuberous sclerosis complex (TSC) gene changes. One case illustrates severe, multi-organ TSC with LAM and bleeding kidney tumors, while another shows a uterine tumor (a PEComa) that had areas resembling LAM and required specialized testing to classify correctly. Taken together, these cases emphasize that LAM biology overlaps with a family of TSC-related tumors, and that careful diagnosis can matter when findings occur outside the lungs. [3] [4]

In the TSC case, a woman in her mid-30s had lung cysts consistent with LAM along with kidney angiomyolipomas that had hemorrhaged, and genetic testing identified three pathogenic TSC2 variants. The report described a complicated course with multisystem involvement, and she died about 6 months after discharge after declining mTOR inhibitor therapy. As a single patient experience, it cannot predict what will happen for others, but it highlights how severe disease can look when multiple organs are involved. [3]

In the uterine tumor case, a 58-year-old woman was ultimately diagnosed with a uterine PEComa with LAM-like features after pathology testing and molecular testing found a TSC1 frameshift mutation. The tumor had extensive lymphovascular invasion, but early follow-up imaging at 2 and 6 months after surgery showed no metastasis, and recovery was uncomplicated. This case mainly shows that some tumors can mimic other diagnoses at first and may need a combined pathology and genetic workup to label them correctly. [4]

What this may mean for patients and caregivers

For patients, these reports do not change day-to-day care, but they add context about the range of TSC-related conditions that can overlap with LAM, including growths in organs like the kidneys or uterus. They also reinforce that when a person has LAM with signs in other organs, genetic and pathology testing can sometimes clarify whether TSC gene changes are involved or whether a tumor has LAM-like features. Because both papers are single-patient reports, they mainly serve as early signals and learning examples rather than evidence about what is common or what outcomes to expect. [3] [4]